Canada Pension Plan Investment Board Sells 1,053,385 Shares of Boston Scientific Corporation $BSX

Key Points

• The Canada Pension Plan Investment Board reduced its stake in Boston Scientific Corporation by 14.5%, holding approximately $629.04 million in shares after selling over one million shares in the first quarter.
• Boston Scientific reported a quarterly EPS of $0.75, surpassing estimates, with revenue reaching $5.06 billion, reflecting a 22.8% year-over-year increase.
• Analysts maintain a positive outlook on Boston Scientific, with a consensus rating of "Buy" and an average price target of $117.50 for the stock.

Canada Pension Plan Investment Board trimmed its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 14.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,235,563 shares of the medical equipment provider's stock after selling 1,053,385 shares during the quarter. Canada Pension Plan Investment Board owned about 0.42% of Boston Scientific worth $629,044,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $27,000. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $25,000. Colonial Trust Co SC lifted its position in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares during the last quarter. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at $31,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Down 1.1%

Boston Scientific stock traded down $1.22 during mid-day trading on Wednesday, hitting $105.44. 3,263,581 shares of the company's stock were exchanged, compared to its average volume of 7,454,697. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $156.24 billion, a P/E ratio of 62.82, a P/E/G ratio of 2.54 and a beta of 0.65. Boston Scientific Corporation has a 1-year low of $80.50 and a 1-year high of $108.94. The stock has a 50 day moving average of $104.65 and a two-hundred day moving average of $102.14.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 124,214 shares of company stock valued at $13,125,957. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BSX. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Citigroup reissued a "buy" rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. UBS Group boosted their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.